ClinicalTrials.gg
Status unknownNCT02976675Updated Jun 16, 2017

Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency

A Phase 4 interventional study of PEG-somatropin and PEG-somatropin in Growth Hormone Deficiency, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Status unknown at 24 sites in China. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2017-06-16.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Planned enrollment
4th of 60
600 · median 66
Started
2015
with 2 others
Phase 4
19 of 60
none open now
Registered
52nd of 60
by date
Lead sponsor
10 of 60
Changchun GeneScience Pharmaceutical Co., Ltd.

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 4th largest by planned enrollment, is one of 3 that started in 2015, is one of 19 in phase 4, and was the 52nd registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 3 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of PEG Somatropin Injection in the treatment of children with growth hormone deficiency, as well as to study the feasibility of extending the dosing intervals (once per two weeks) of PEG Somatropin Injection.

03

Conditions studied

  • Growth Hormone Deficiency

Browse trials for

04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects are diagnosed as GHD before starting treatment, according to medical history, clinical symptoms and signs, GH provocation tests and imaging and other examinations:

    1. According to statistical height data of physical development of Chinese children in nine cities in 2005, the height is lower than 3rd percentile growth curve of the same age, same sex normal children;
    2. Height velocity (HV) ≤5.0 cm / yr;
    3. GH provocative tests (with two drugs of different mechanism of action) confirmed plasma GH peak \<10.0 ng / ml;
    4. bone age for girl≤9 years old, for Boy≤10 years old, bone age is one year or more later than the actual age, that is the actual age - bone age ≥ 1 year;
  • Before puberty (Tanner I stage), age≥3 years old, male or female;
  • Subjects have not received hormone therapy within 6 months;
  • Subjects is willing and able to cooperate to complete scheduled visits, treatment plans and laboratory tests and other procedures, to sign .

Exclusion criteria

Exclusion Criteria:

  • Dysfunction of liver and kidney (> 2 times the , Cr> upper limit of normal);
  • Patients positive for c-antibody (HBcAb), hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg);
  • Patients with known to PEG Somatropin or Somatropin or any other components of the study product;
  • Patients with severe cardiopulmonary or hematological diseases, a current or past history of malignant tumors, immunodeficiency diseases, or mental diseases;
  • Potential cancer patients (family history);
  • Patients with diabetics;
  • Patients with other growth disorders, such as Turner's syndrome, sexual physical delayed puberty, Laron syndrome, growth hormone receptor deficiency, girls with slowly growing who did not rule out chromosomal abnormalities;
  • Patients with congenital bone dysplasia or scoliosis;
  • Subjects took part in other clinical trial study during 3 months;
  • Other conditions in which the investigator preclude enrollment into the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    PEG-somatropin

    Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks

    Biological: PEG-somatropin

  • Experimental
    PEG-somatropin per two weeks

    Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit Group of dosing per two weeks:0.20 mg /kg/2w,once per two weeks for 26 weeks

    Biological: PEG-somatropin

  • Active comparator
    Jintropin AQ

    Jintropin AQ, injection, 30IU/10 mg/3ml/cartridge, 0.25mg/kg/w, once per day for 26 weeks

    Biological: PEG-somatropin

Interventions

  • BiologicalPEG-somatropin

    Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks

  • BiologicalPEG-somatropin

    Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per two weeks:0.20 mg /kg/2w,once per two weeks for 26 weeks

06

What researchers measure

Primary outcomes

  1. Ht SDSca

    Ht SDSca was calculated by dividing the difference between the actual height of a patient and the mean height of the population for that chronological age by the standard deviation (SD) of the height of the population for that chronological age

    Time frame: Baseline, 4,12,26 weeks after initiating treatment

Secondary outcomes

  1. Ht SDSBA

    Calculate by formula

    Time frame: Baseline, 4,12,26 weeks after initiating treatment

  2. Yearly growth velocity

    Calculate by formula

    Time frame: Baseline, 4,12,26 weeks after initiating treatment

  3. IGF-1SDS

    Calculate by formula

    Time frame: Baseline, 4,12,26 weeks after initiating treatment

  4. IGF-1/IGFBP-3 molar ratio

    Calculate by formula

    Time frame: Baseline, 4,12,26 weeks after initiating treatment

  5. Bone age

    Calculate by formula

    Time frame: Baseline, 4,12,26 weeks after initiating treatment

07

Study locations

24 of 24 sites recruiting
  • Maternal and Child Health Hospital of Anhui province
    Hefei, Anhui, China
    Recruiting
  • First People's Hospital of Lu'an City
    Lu'an, Anhui, China
    Recruiting
  • Second Hospital of Lanzhou University
    Lanzhou, Gansu, China
    Recruiting
  • Maternal and Child Health Hospital of Guiyang City
    Guiyangtou, Guizhou, China
    Recruiting
  • Maternal and Child Health Hospital of Hainan province
    Haikou, Hainan, China
    Recruiting
  • Hebei Provincial People's Hospital
    Shijiazhuang, Hebei, China
    Recruiting
  • First Affiliated Hospital of Henan University of Science and Technology
    Zhengzhou, Henan, China
    Recruiting
  • Maternal and Child Health Hospital of Hubei province
    Wuhan, Hubei, China
    Recruiting
  • First People's Hospital of Changzhou City
    Changzhou, Jiangsu, China
    Recruiting
  • First People's Hospital of Lianyungang City
    Lianyungang, Jiangsu, China
    Recruiting
  • Jiangsu Provincial Hospital of Chinese Traditional medicine
    Nanjingkou, Jiangsu, China
    Recruiting
  • Affiliated Hospital of Nantong University
    Nantong, Jiangsu, China
    Recruiting
  • Suzhou City Hospital
    Suzhou, Jiangsu, China
    Recruiting
  • Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
    Recruiting
  • Maternal and Child Health Hospital of Tai'an city
    Tai'an, Shandong, China
    Recruiting
  • Children's Hospital of Chengdu city
    Chengdu, Sichuan, China
    Recruiting
  • People's Hospital of Cixi City
    Cixi, Zhejiang, China
    Recruiting
  • First People's Hospital
    Hangzhou, Zhejiang, China
    Recruiting
  • First People's Hospital of Jiaxing City
    Jiaxing, Zhejiang, China
    Recruiting
  • Jinhua Central Hospital
    Jinhua, Zhejiang, China
    Recruiting
  • Jishuitan Hospital of Beijing City
    Beijing, China
    Recruiting
  • Peoples' hospital of Inner Mongolia Autonomous Region
    Inner Mongolia Autonomous Region, China
    Recruiting
  • General Hospital of Ningxia Medical University
    Ningxia Autonomous Region, China
    Recruiting
  • Children's Hospital of Fudan University
    Shanghai, China
    Recruiting
08

References and documents

Publications

  • Sun C, Lu B, Liu Y, Zhang Y, Wei H, Hu X, Hu P, Zhao Q, Liu Y, Ye K, Wang K, Gu Z, Liu Z, Ye J, Zhang H, Zhu H, Jiang Z, Liu Y, Wan N, Yan C, Yin J, Ying L, Huang F, Yin Q, Xi L, Luo F, Cheng R. Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial. Front Endocrinol (Lausanne). 2021 Nov 25;12:779365. doi: 10.3389/fendo.2021.779365. eCollection 2021. Erratum In: Front Endocrinol (Lausanne). 2021 Dec 28;12:830469. doi: 10.3389/fendo.2021.830469. PubMed 34899612 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015 and a primary completion of Jun 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2016
First posted
Nov 29, 2016
Start
Jan 2015
Primary completionEst.
Jun 2017
Last update
Jun 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02976675
Collaborators
Children's Hospital of Fudan University, Suzhou Municipal Hospital, General Hospital of Ningxia Medical University, The First Affiliated Hospital of Henan University of Science and Technology, Maternal and Child Health Hospital of Hubei Province, Nantong University
Responsible party
Sponsor
First posted
Nov 29, 2016
Start date
Jan 2015
Primary completion
Jun 2017 (estimated)
Last update
Jun 16, 2017

Study contacts

Xiaohua Feng
Contact
fengxiaohua@gensci-china.com
13610794989
Feihong Luo, Doctor
principal investigator · Children's Hospital of Fudan University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion